Professor Johann de Bono’s team conducts biomarker-driven clinical and translational research to accelerate the development of novel cancer therapies The Cancer Biomarker Team now has a vacancy for an Animal Technician or mid-level Scientific Officer to support the preclinical work using genetically modified mouse models and patient as well as cell line derived xenograft models. The applicant ideally holds a PIL and should have some experience with animal-based research, but training will be provided where necessary.
Key Requirements
The main objective of this post is to provide technical support to the Cancer Biomarkers Team thereby helping to further characterize advanced prostate cancer and to validate novel therapeutic targets. This includes the day-to-day care and maintaining our high standards of animal welfare for our mouse colony as well as conducting treatment and measurements for our preclinical studies.
The ideal post holder has a qualification in Animal Technology or other suitable qualification and experience in preclinical research, ideally with prostate cancer. Experience in managing mouse knockout and transgenic breeding colonies would be highly advantageous along with the ability to conduct drug treatments (injections and oral gavage), as well as minor surgery such as such as castration, implantation of tumours into various sites, but support and training will be given where necessary. The successful candidate will be part of our research team. We are looking for an open minded, dedicated, focused, motivated to improve patient care and excited to work in vibrant research environment.
Department/Directorate Information
Professor Johann de Bono’s team conducts biomarker-driven clinical and translational research to accelerate the development of novel cancer therapies and improve understanding of cancer biology, drug sensitivity and resistance. His team focuses on improving prostate cancer care that have led pivotal phase III trials of several prostate cancer drugs including abiraterone, cabazitaxel, enzalutamide and olaparib as well more recently ipatasertib and lutetium-PSMA. His team consists of basic and clinical scientists, which is embedded in a vibrant world-class research environment.